Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research

SAN DIEGO--(BUSINESS WIRE)-- Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders announced today that it received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative disorders.

“We are very pleased with the progress we have achieved on the TLR2 program and to receive this second grant from The Michael J. Fox Foundation. This grant will enable us to accelerate our efforts to identify and optimize small molecule TLR2 antagonists as well as to build the foundation for a translational biomarker platform focused on clinically-relevant endpoints,” stated Douglas Bonhaus, Chief Scientific Officer of Neuropore.

Neuropore Therapies is developing an exciting pipeline of potential therapeutics aimed at the major components of neurodegenerative diseases, including the aggregation of pathological proteins, misfolded protein clearance and neuroinflammation.

About Neuropore Therapies, Inc. (NPT^®)

Neuropore Therapies, Inc. is a San Diego, California based biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for the treatment of neurodegenerative diseases. The approaches being taken by Neuropore target the underlying pathological processes that are common across many of these disorders – the intracellular accumulation of neurotoxic misfolded protein aggregates and the associated neuroinflammatory responses. Neuropore’s therapeutic candidates prevent the formation, mitigate the toxicity and/or enhance the destruction of these toxic proteins.

Neuropore Therapies is developing a sustainable pipeline of novel therapeutic candidates. The first clinical candidate to emerge from our discovery efforts is NPT200-11. This is an orally bioavailable small molecule that uniquely targets the earliest steps in the formation of alpha-synuclein (ASYN) toxic oligomeric protein aggregates involved in Parkinson’s disease (PD) and other related disorders. NPT200-11 is partnered with UCB Pharma and is progressing in clinical trials for the treatment of PD. Beyond the continuing development of NPT200-11, Neuropore Therapies is advancing a number of additional preclinical stage compounds, with complementary mechanisms of action. The most advanced compound is NPT520-34, an orally bioavailable, brain penetrant anti-inflammatory agent that robustly attenuates aberrant microglial and astroglial responses and decreases the accumulation of ASYN. NPT520-34 has a well-defined biomarker/imaging strategy developed for early proof-of-mechanism studies in Parkinson’s patients and is currently in pre-clinical development with an IND filing projected for 4Q18/1Q19. Neuropore’s TLR2 antagonist program has identified structurally novel, orally bioavailable and brain penetrating small molecule leads. The TLR2 program is currently in lead optimization and the goal is to select candidate for treatment of neurodegenerative diseases in 2018.

To lean more, visit www.Neuropore.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005015/en/